If you look at the opportunity for biosimilar in the targeted markets especially US and European markets, we believe that this is a very realistic number which we can definitely deliver on because if you think about the projections of the biosimilar market which in 2018 in the US and Europe alone was USD 2.9 billion and is projected to increase to almost USD 14 billion by 2025 in which the portfolio that Mylan and Biocon is addressing is a substantial part of this USD 14 billion opportunity and this does not include the insulin portfolio that we also have.